Tumor Blood Vessel Antigens

Tumor blood vessel antigens refer to a diverse group of molecules uniquely or highly expressed on the endothelial cells and pericytes of blood vessels within tumors, distinguishing them from normal vasculature. These antigens play a critical role in tumor angiogenesis, the process by which new blood vessels form to supply the growing tumor with oxygen and nutrients, which is essential for tumor growth and metastasis. The tumor vasculature is often abnormal, disorganized, and leaky, contributing to an immunosuppressive tumor microenvironment. Targeting these antigens is a key strategy in cancer therapy, aiming to inhibit blood vessel formation, disrupt existing vessels, or normalize the tumor vasculature to improve drug delivery and immune cell infiltration. Common targets include Vascular Endothelial Growth Factors (VEGFs) and their Receptors (VEGFRs), Integrins, Fibroblast Growth Factors (FGFs), and Platelet-Derived Growth Factors (PDGFs). Drugs interacting with these targets include monoclonal antibodies (e.g., Bevacizumab) and tyrosine kinase inhibitors (e.g., Sunitinib, Sorafenib). While effective in many cancers, anti-angiogenic therapies can lead to safety concerns such as hypertension, bleeding, and cardiovascular toxicities, and tumors can develop resistance.

Other names

Tumor-associated vascular antigensTumor vasculature targetsAngiogenesis targets

Drugs targeting tumor blood vessel antigens primarily work by inhibiting angiogenesis, the process of new blood vessel formation, thereby starving tumors of essential oxygen and nutrients. This is often achieved by blocking pro-angiogenic factors like Vascular Endothelial Growth Factor (VEGF) or their receptors (VEGFRs) on endothelial cells, which are crucial for endothelial cell proliferation, migration, and survival. Some agents, known as vascular disrupting agents, directly destroy established tumor blood vessels. Another mechanism involves normalizing the chaotic tumor vasculature, which can improve the delivery of chemotherapy and enhance immune cell infiltration into the tumor. Tyrosine kinase inhibitors (TKIs) act by inhibiting intracellular signaling pathways critical for angiogenesis. Additionally, some therapies modulate the immune response within the tumor microenvironment to enhance anti-tumor immunity.